Skip to main content
OpenTrials
Completed

NCT Number: NCT01161563

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

The purpose of this study is to compare how subjects feel after receiving injections of two different types of GnRH six months apart. One injection is given under the skin of the abdomen, and the other one into the muscle of the buttock or thigh.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 4

Primary location

Watson Investigational Site, Homewood, Alabama, United States

Loading trial locations.

About this study

GnRH is given as an injection. Injections of GnRH can be uncomfortable, causing a feeling of burning or stinging. The uncomfortable feeling may be caused by differences in the types of GnRH and the site of the injection (under the skin of the abdomen, or into the muscle of the buttock or thigh).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male patients with a diagnosis of advanced prostate cancer for whom treatment with triptorelin pamoate or leuprolide acetate is indicated;
  • At least 18 years of age;
  • Life expectancy of at least 1 year;
  • Capable of completing the study questionnaires without assistance.

Exclusion criteria

  • Patients for whom treatment with triptorelin pamoate or leuprolide acetate is contraindicated;
  • Known hypersensitivity to triptorelin, leuprolide or any other GnRH or luteinizing hormone releasing hormone (LHRH) agonists, or GnRH or LHRH;
  • Clinically significant systemic disease or condition that would, in the investigator's opinion, lead to undue risk following administration of either triptorelin or leuprolide;
  • History of alcohol/drug abuse within the past year;
  • History of significant medical problems that may confound the outcome of this study;
  • Requires concomitant medications that may affect study assessments (e.g., topical medications used for pretreatment of injection site pain);
  • Participated in another investigational drug study within 30 days
  • Judged by the investigator to be unsuitable for enrollment in this study for any reason

Treatment and study plan

Triptorelin Pamoate

Drug

Triptorelin pamoate for injectable suspension 22.5 mg administered as a single intramuscular injection in either buttock

Leuprolide Acetate

Drug

Leuprolide acetate for injectable suspension 45 mg administered as a single subcutaneous injection in the upper- or mid-abdominal area.

Primary outcomes

  1. Patient Bother From Injection Site Burning and/or Stinging

    Time frame: 15 minutes

    Questionnaire responses recorded on a Visual Analog Scale (VAS), which has a range of 0-100 mm, assessed approximately 15 minutes post-injection

Secondary outcomes

  1. Discomfort From Injection

    Time frame: 15 minutes

    Questionnaire responses recorded on a Visual Analog Scale (VAS), which has a range of 0-100 mm, assessed approximately 15 minutes post-injection

Sponsors and collaborators

Lead sponsor

Watson Pharmaceuticals

Industry

Registry information

Official study title

Randomized Crossover Trial to Assess the Tolerability of GnRH Analogue Administration in Patients With Advanced Prostate Cancer

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Jul 13, 2010
Registry last updated
Sep 6, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.